Chang Lei, Graham Peter, Hao Jingli, Ni Jie, Deng Junli, Bucci Joseph, Malouf David, Gillatt David, Li Yong
Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.
St George and Sutherland Clinical School, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia.
Oncotarget. 2016 Mar 8;7(10):11002-17. doi: 10.18632/oncotarget.6760.
Radiation therapy (RT) is one of the most important strategies in cancer treatment. Radioresistance (the failure to RT) results in locoregional recurrence and metastasis. Therefore, it is critically important to investigate the mechanisms leading to cancer radioresistance to overcome this problem and increase patients' survival. Currently, the majority of the radioresistance-associated researches have focused on preclinical studies. Although the exact mechanisms of cancer radioresistance have not been fully uncovered, accumulating evidence supports that cancer stem cells (CSCs) and different signaling pathways play important roles in regulating radiation response and radioresistance. Therefore, targeting CSCs or signaling pathway proteins may hold promise for developing novel combination modalities and overcoming radioresistance. The present review focuses on the key evidence of CSC markers and several important signaling pathways in cancer radioresistance and explores innovative approaches for future radiation treatment.
放射治疗(RT)是癌症治疗中最重要的策略之一。放射抗性(对RT无反应)会导致局部区域复发和转移。因此,研究导致癌症放射抗性的机制对于克服这一问题并提高患者生存率至关重要。目前,大多数与放射抗性相关的研究都集中在临床前研究。尽管癌症放射抗性的确切机制尚未完全揭示,但越来越多的证据支持癌症干细胞(CSCs)和不同的信号通路在调节放射反应和放射抗性中发挥重要作用。因此,靶向CSCs或信号通路蛋白可能为开发新型联合治疗方法和克服放射抗性带来希望。本综述重点关注CSC标志物和癌症放射抗性中几个重要信号通路的关键证据,并探索未来放射治疗的创新方法。